mRNA-1273 vaccine (Moderna): a better option than BNT162b2 (Pfizer) in kidney transplant recipients and dialysis patients? (preprint)

In this study of the humoral immune response after the first dose of SARS-CoV-2 mRNA vaccine, low seroconversion rates were noted in both kidney transplant recipients and dialysis patients. However, vaccination with the mRNA-1273 vaccine (Moderna) resulted in both higher seroconversion rates and mean antibody titers compared to BNT162b2 (Pfizer).